{"schema_version":"1.0","type":"article","title":"大藥廠 輝瑞在兩個判斷上栽跟頭？","url":"https://drugnews.com.tw/articles/2026-05-18-pfizer-vepdegestrant-strategy-mistake.html","markdown_url":"https://drugnews.com.tw/articles/2026-05-18-pfizer-vepdegestrant-strategy-mistake.md","lang":"zh-Hant","date":"2026-05-18","publish_at":"2026-05-18T10:30:00+08:00","updated_at":"2026-05-18","category":"商業分析系列","topic":"商業分析系列","tags":["Dcard","免費文章","BD","ADC","PROTAC","FDA","Pfizer","Gilead"],"summary":"【「賤賣」重磅炸彈，Pfizer 為何在兩個判斷上栽跟頭？】Pfizer 正站在一個很微妙的十字路口。一邊，是它與 Arvinas 聯手研發的 Vepdegestrant（Veppanu） 獲 FDA","key_points":[],"facts":[],"sections":["01｜CD47：23 億美元買來的「別吃我」幻夢","02｜Gedatolisib：被 Pfizer 太早放手的乳癌武器","03｜Vepdegestrant：Pfizer 也不是只會看錯","04｜大型藥廠最難的不是買，而是判斷什麼該留","05｜台灣的CD47"],"references":[{"title":"[0]: 各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"reuters.com","source":"","date":"","url":""},{"title":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-pfizer-arvinas-breast-cancer-drug-2026-05-01/","source":"","date":"","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-pfizer-arvinas-breast-cancer-drug-2026-05-01/"},{"title":"www.reuters.com","source":"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"Pfizer’s $2.3B bet ends in failure as CD47 blocker scrapped","source":"","date":"","url":""},{"title":"The Big Pharma has abandoned the second and final clinical-stage candidate from the Trillium acquisition.","source":"","date":"","url":""},{"title":"www.fiercebiotech.com","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"Celcuity Stock Triples on Positive Breast Cancer Treatment Study","source":"","date":"","url":""},{"title":"Celcuity shares skyrocketed to an all-time high when the biotech reported positive results from a Phase 3 trial of its treatment for certain kinds of breast cancer.","source":"","date":"","url":""},{"title":"www.investopedia.com","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"Pfizer Ends Mid-Stage Trial for CD47 Blood Cancer Drug, Citing Recruitment Problems - BioSpace","source":"","date":"","url":""},{"title":"Pfizer insists that the discontinuation of the Phase II study was due to recruitment difficulties and was not linked to maplirpacept’s safety or efficacy.","source":"","date":"","url":""},{"title":"www.biospace.com","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"生技股添新兵 漢康6月20日登興櫃聚焦免疫腫瘤創新藥","source":"生醫產業熱點","date":"","url":""},{"title":"生技股添新兵，專注於免疫腫瘤的創新生物藥開發的漢康 - KY(7827-TW) 將於 6 月 20 日登興櫃。漢康以自建 FBDB 平台為基礎，開發融合蛋白生物藥，專攻腫瘤細胞的免疫偽裝路徑 SIRPα/CD47，具有突破現有 PD-1/PD-L1 免疫療法的潛力。","source":"","date":"","url":""},{"title":"www.biotech-edu.com","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：大藥廠 輝瑞在兩個判斷上栽跟頭？","url":"https://drugnews.com.tw/assets/articles/pfizer-vepdegestrant-strategy-mistake/dcard-01.webp"},{"alt":"Dcard 原圖：大藥廠 輝瑞在兩個判斷上栽跟頭？","url":"https://drugnews.com.tw/assets/articles/pfizer-vepdegestrant-strategy-mistake/dcard-02.png"},{"alt":"Dcard 原圖：大藥廠 輝瑞在兩個判斷上栽跟頭？","url":"https://drugnews.com.tw/assets/articles/pfizer-vepdegestrant-strategy-mistake/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/pfizer-vepdegestrant-strategy-mistake/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-05-18）。大藥廠 輝瑞在兩個判斷上栽跟頭？。https://drugnews.com.tw/articles/2026-05-18-pfizer-vepdegestrant-strategy-mistake.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-05-18-pfizer-vepdegestrant-strategy-mistake-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}